Journal article
A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H3 Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer's Disease
RA Grove, CM Harrington, A Mahler, I Beresford, P Maruff, MT Lowy, AP Nicholls, RL Boardley, AC Berges, PJ Nathan, JP Horrigan
Current Alzheimer Research | Published : 2014
Abstract
Introduction: Histaminergic H3 receptors may play a role in modulating cholinergic and monoaminergic neurotransmission. This Phase II study evaluated the efficacy and safety of GSK239512, a highly potent, brain penetrant H3 receptor antagonist as monotherapy treatment for subjects with mild-to-moderate probable Alzheimer's disease (AD). Methods: In this 16-week, double-blind, randomized, parallel group study, 196 currently untreated subjects with mild-to-moderate AD (Mini Mental State Examination [MMSE] 16-24) received GSK239512 (n=97); or placebo (n=99) administered orally each morning. After a two-week placebo run-in period GSK239512 was up-titrated over 4 weeks in a flexible manner (10-20..
View full abstractGrants
Funding Acknowledgements
Funding for this study was provided by GlaxoSmithKline (NCT01009255). All listed authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors.